{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:47:38Z","timestamp":1787071658098,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cancer of unknown primary (CUP) is characterized by metastatic cancer cells with no identifiable primary tumor despite extensive diagnostics. This study investigates the epidemiologic, histopathological, and prognostic factors in 352 CUP cases in Iran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This retrospective study reviewed the clinical documents of CUP patients registered in MACSA, a charity-based referral center in central Iran, Isfahan, within 2016\u20132021. The patients\u2019 data were analyzed, and survival associations were assessed using Cox proportional hazards regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Altogether 352 CUP patients were included in the study. The mean age at diagnosis was 65.9 \u00b1 14.3 years, with 52.6% being male. Abdominal pain (32.1%) was the most common presentation. Metastatic adenocarcinoma (31.5%) was the most frequent histopathological type, with the liver (48.6%) as the most prevalent metastatic site. Single-site metastasis was seen in 55.4% of patients. Immunohistochemistry, conducted in 40.3% of patients, was inconclusive in identifying the primary site. The median overall survival was 5 months (95% confidence interval [CI]: 4.0\u20137.0). Multivariable Cox regression analysis showed older age increased risk of death (hazard ratio [HR]: 1.028, 95% CI: 1.019\u20131.037). Neuroendocrine tumors were linked to a lower risk (HR: 0.553, 95% CI: 0.313\u20130.978), while metastasis to the liver (HR: 1.382, 95% CI: 1.076\u20131.774) and pancreas (HR: 2.138, 95% CI: 1.094\u20134.176) increased mortality risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study provides large-scale evaluation of CUP in an Iranian population, revealing its poor prognosis and the limited diagnostic utility of IHC. The findings align with global data and highlight the urgent need for improved diagnosis and treatment to enhance patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrms.jrms_520_24","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:08:03Z","timestamp":1759234083000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiologic, histopathological, and prognostic analysis of cancer of unknown primary in an Iranian population"],"prefix":"10.4103","volume":"30","author":[{"given":"Mohammad","family":"Rayati","sequence":"first","affiliation":[{"name":"Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Iranian Cancer Control Center (MACSA), Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzeh","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Heidarpour","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Najafizade","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Zeinalian","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Iranian Cancer Control Center (MACSA), Isfahan, Iran"},{"name":"Pediatric Inherited Disease Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9]]},"reference":[{"key":"R1-20250930","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1186\/s12885-022-10472-z","article-title":"Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"R3-20250930","doi-asserted-by":"crossref","first-page":"m4050","DOI":"10.1136\/bmj.m4050","article-title":"Cancer of unknown primary","volume":"371","author":"Lee","year":"2020","journal-title":"BMJ"},{"key":"R4-20250930","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41591-024-02915-w","article-title":"Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning","volume":"30","author":"Tian","year":"2024","journal-title":"Nat Med"},{"key":"R5-20250930","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12885-023-10794-6","article-title":"Risk factors for cancer of unknown primary: A literature review","volume":"23","author":"Hermans","year":"2023","journal-title":"BMC Cancer"},{"key":"R6-20250930","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3389\/fonc.2019.01546","article-title":"Metastatic cancer of unknown primary or \u201cprimary metastatic cancer\u201d?","volume":"9","author":"Kolling","year":"2019","journal-title":"Front Oncol"},{"key":"R7-20250930","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.critrevonc.2008.09.005","article-title":"Carcinoma of unknown primary (CUP)","volume":"69","author":"Pavlidis","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"R8-20250930","doi-asserted-by":"crossref","first-page":"e005809","DOI":"10.1136\/jitc-2022-005809","article-title":"Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary","volume":"11","author":"Posner","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R9-20250930","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10555-023-10101-6","article-title":"Carcinoma of unknown primary (CUP): An update for histopathologists","volume":"42","author":"Beauchamp","year":"2023","journal-title":"Cancer Metastasis Rev"},{"issue":"Suppl 5","key":"R11-20250930","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"key":"R12-20250930","first-page":"e5552","article-title":"Cancer of unknown primary: A review on clinical guidelines in the development and targeted management of patients with the unknown primary site","volume":"11","author":"Qaseem","year":"2019","journal-title":"Cureus"},{"key":"R13-20250930","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1038\/s41467-022-31866-4","article-title":"Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity","volume":"13","author":"M\u00f6hrmann","year":"2022","journal-title":"Nat Commun"},{"key":"R14-20250930","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamaoncol.2015.4265","article-title":"Familial risk in patients with carcinoma of unknown primary","volume":"2","author":"Samadder","year":"2016","journal-title":"JAMA Oncol"},{"key":"R15-20250930","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann Oncol"},{"key":"R16-20250930","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12967-018-1564-x","article-title":"Genetic characterisation of molecular targets in carcinoma of unknown primary","volume":"16","author":"Clynick","year":"2018","journal-title":"J Transl Med"},{"key":"R17-20250930","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","article-title":"Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy","volume":"94","author":"Gatalica","year":"2018","journal-title":"Eur J Cancer"},{"key":"R18-20250930","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdv543","article-title":"Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)","volume":"27","author":"Yoon","year":"2016","journal-title":"Ann Oncol"},{"key":"R19-20250930","doi-asserted-by":"crossref","first-page":"44322","DOI":"10.18632\/oncotarget.10035","article-title":"Molecular driver alterations and their clinical relevance in cancer of unknown primary site","volume":"7","author":"L\u00f6ffler","year":"2016","journal-title":"Oncotarget"},{"key":"R20-20250930","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ctrv.2013.03.001","article-title":"Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature","volume":"39","author":"Petrakis","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"R21-20250930","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13000-024-01461-w","article-title":"Quantitative assessment of H and E staining for pathology: Development and clinical evaluation of a novel system","volume":"19","author":"Dunn","year":"2024","journal-title":"Diagn Pathol"},{"key":"R22-20250930","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/bjc.1998.395","article-title":"A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)","volume":"77","author":"Warner","year":"1998","journal-title":"Br J Cancer"},{"key":"R23-20250930","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-007-0604-7","article-title":"Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study","volume":"62","author":"Briasoulis","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R24-20250930","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1080\/02841860701843043","article-title":"Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study","volume":"47","author":"Pentheroudakis","year":"2008","journal-title":"Acta Oncol"},{"key":"R25-20250930","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cncr.29229","article-title":"Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial","volume":"121","author":"Hainsworth","year":"2015","journal-title":"Cancer"},{"key":"R26-20250930","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejca.2012.01.011","article-title":"Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial","volume":"48","author":"Gross-Goupil","year":"2012","journal-title":"Eur J Cancer"},{"key":"R27-20250930","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604818","article-title":"Paclitaxel and carboplatin versus gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: A randomised prospective phase II trial","volume":"100","author":"Huebner","year":"2009","journal-title":"Br J Cancer"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_520_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:50:30Z","timestamp":1787068230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_520_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_520_24","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-09-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}